Impact of immunosuppressive therapy on recurrence of hepatitis C

Gregory T. Everson – 30 December 2003 – 1Approximately 10% to 25% of hepatitis C virus–infected recipients of liver allografts will develop cirrhosis within 5 years of transplantation; this acceleration of the natural history of hepatitis C is caused in part by immunosuppression.2Risk factors for aggressive recurrence, graft loss, and death are treated acute cellular rejection, methylprednisolone pulse therapy, and use of OKT3.

The effect of changes in hepatocyte membrane potential on immediate‐early proto‐oncogene expression following partial hepatectomy in rats

G Y Minuk, B T Kren, R Xu, X Zhang, F Burczynski, N P Mulrooney, G Fan, Y Gong, C J Steer – 30 December 2003 – The stimulus responsible for inducing hepatocytes to enter the cell cycle following partial hepatectomy (PHx) remains to be identified. One suggested candidate is the change in hepatocyte membrane potential (PD) that occurs immediately following PHx.

Reperfusion after liver transplantation in rats differentially activates the mitogen‐activated protein kinases

C A Bradham, R F Stachlewitz, W Gao, T Qian, S Jayadev, G Jenkins, Y Hannun, J J Lemasters, R G Thurman, D A Brenner – 30 December 2003 – The injury resulting from cold ischemia and warm reperfusion during liver transplantation is a major clinical problem that limits graft success. Kupffer cell activation plays a pivotal role in reperfusion injury, and Kupffer cell products, including free radicals and tumor necrosis factor α (TNF‐α), are implicated as damaging agents.

Hrp12, a novel heat‐responsive, tissue‐specific, phosphorylated protein isolated from mouse liver

S J Samuel, S P Tzung, S A Cohen – 30 December 2003 – Previous studies from this laboratory identified a 28‐kd nonreducible protein, liver‐derived immunoinhibitory factor (LDIF) from the mouse liver. Isolation of this protein resulted in the co‐purification of another unique protein called heat responsive protein 12 kd (Hrp12). In contrast to LDIF, Hrp12 was totally reducible to a protein of 12 kd suggesting a dimer.

Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand

S Issaragrisil, D Kaufman, A Thongput, K Chansung, T Thamprasit, A Piankijagum, T Anderson, S Shapiro, P Leaverton, N S Young – 30 December 2003 – Aplastic anemia is more common in the Orient than in western countries, with an incidence in Thailand that is 2‐ to 3‐fold higher than in Europe. Aplastic anemia after hepatitis is a well characterized clinical entity, and clinical hepatitis is also prevalent in the Far East. We performed a prospective case‐control study to determine risk factors for aplastic anemia in Bangkok and two rural regions during 1989 to 1994.

Hepatitis G virus co‐infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease

M W Fried, Y E Khudyakov, G A Smallwood, M Cong, B Nichols, E Diaz, P Siefert, K Gutekunst, R D Gordon, T D Boyer, H A Fields – 30 December 2003 – Hepatitis G virus (HGV) is a newly described RNA virus that is parenterally transmitted and has been found frequently in patients with chronic hepatitis C infection.

Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans

P Loria, M Bozzoli, M Concari, M E Guicciardi, F Carubbi, M Bertolotti, D Piani, A Nistri, M Angelico, M Romani, N Carulli – 30 December 2003 – This study aimed to determine the effect in humans of taurohyodeoxycholic acid, a 6α‐hydroxylated bile acid with hydrophilic properties, on bile lipid secretion. Four cholecystectomized patients who had gallstones and an interrupted enterohepatic circulation were intraduodenally infused with taurohyodeoxycholic and tauroursodeoxycholic acids on separate occasions at a dose of 0.8 to 1 g/h for 3 hours.

Subscribe to